サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777522

網膜静脈閉塞症治療の世界市場

Retinal Vein Occlusion Treatment

出版日
ページ情報
英文 373 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
網膜静脈閉塞症治療の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 373 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

網膜静脈閉塞症治療の世界市場は2030年までに39億米ドルに到達

2024年に28億米ドルと推定される網膜静脈閉塞症治療の世界市場は、2024～2030年の分析期間においてCAGR 6.0％で成長し、2030年には39億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである網膜中心静脈閉塞症は、CAGR 6.9％を記録し、分析期間終了までに29億米ドルに達すると予測されます。網膜静脈分枝閉塞症セグメントの成長率は、分析期間中CAGR 4.0％と推定されます。

米国市場は7億4,940万米ドルと推定、中国はCAGR9.7％で成長予測

米国の網膜静脈閉塞症治療市場は、2024年に7億4,940万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.7%で推移し、2030年までに8億410万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.0%と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界の網膜静脈閉塞症治療市場- 主要動向と促進要因まとめ

なぜ効果的な網膜静脈閉塞症（RVO）治療の重要性が高まっているのか？

網膜静脈閉塞症（RVO）は視力障害の主要な原因であり、高血圧、糖尿病、心血管疾患などの基礎疾患と関連していることが多いです。RVOは黄斑浮腫や血管新生緑内障などの重篤な合併症を引き起こす可能性があるため、効果的な治療戦略の需要が高まっています。薬物療法、レーザー治療、外科的介入における進歩は患者の転帰を改善し、視力のさらなる悪化を防ぐのに役立っています。高齢化社会の進展と代謝性疾患の有病率の増加は、RVO症例の世界の増加に寄与しています。その結果、ヘルスケアプロバイダーや研究者は、より的を絞った長期的な治療法の開発に注力しています。

技術の進歩はRVOの治療成績をどのように改善しているか？

抗VEGF（血管内皮増殖因子）療法の開発により、RVOに関連した黄斑浮腫の治療状況は一変し、網膜腫脹が大幅に減少し、視力が改善しました。徐放性コルチコステロイドインプラントも導入され、少ない注射回数で長期的な効果が得られるようになりました。さらに、マイクロパルスレーザー療法を含むレーザー光凝固技術の進歩により、副作用を軽減したより正確な治療オプションが提供されています。AIを搭載した診断ツールや網膜画像システムは、早期発見と個別化された治療計画を強化し、RVO患者へのタイムリーな介入を保証しています。さらに、幹細胞治療を含む新たな再生医療アプローチは、損傷した網膜組織を修復し、長期的な予後を改善することが期待されています。

RVO治療の需要を牽引する市場動向とは？

抗VEGF注射とレーザー治療を統合した併用療法の採用が増加しており、治療効果を高めると同時に、医療介入の頻度を減らしています。遠隔眼科サービスの拡大により、早期診断と遠隔モニタリングが容易になり、患者管理が向上しています。さらに、スマートフォンを利用した網膜画像診断など、在宅での視力モニタリング・ソリューションの台頭により、患者は自分の目の健康状態を把握し、適時に診察を受けることができるようになっています。政府が資金提供する網膜疾患スクリーニング・プログラムやヘルスケア償還政策が、市場の成長をさらに後押ししています。遺伝子治療や神経保護など、新しい治療アプローチの研究が進むにつれ、RVO治療市場は急速に発展しています。

RVO治療市場の主な成長促進要因は？

世界の網膜静脈閉塞症治療市場の成長は、糖尿病や高血圧の増加、薬理療法の進歩、網膜イメージング技術の向上が原動力となっています。RVO関連合併症の第一選択治療として抗VEGF療法が広く採用されていることが、市場拡大に大きく寄与しています。さらに、長時間作用型のドラッグデリバリーシステムが利用可能になりつつあることで、患者のコンプライアンスが向上し、治療負担が軽減されています。新興市場におけるヘルスケア・アクセスの拡大や、政府主導の視力ケアへの取り組みが需要をさらに加速しています。RVO治療市場は、新たな治療イノベーションの出現に伴い、世界中の患者に改善されたソリューションを提供し、持続的な成長が見込まれています。

セグメント

疾患タイプ（網膜中心静脈閉塞症、網膜静脈分枝閉塞症）;治療法（抗血管内皮因子薬、副腎皮質ステロイド薬、その他）;エンドユーザー（病院・クリニック、小売薬局、その他）

調査対象企業の例

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.（a member of the Roche Group）
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32818

Global Retinal Vein Occlusion Treatment Market to Reach US$3.9 Billion by 2030

The global market for Retinal Vein Occlusion Treatment estimated at US$2.8 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Central Retinal Vein Occlusion, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Branch Retinal Vein Occlusion segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$749.4 Million While China is Forecast to Grow at 9.7% CAGR

The Retinal Vein Occlusion Treatment market in the U.S. is estimated at US$749.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$804.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Retinal Vein Occlusion Treatment Market - Key Trends & Drivers Summarized

Why Is Effective Retinal Vein Occlusion (RVO) Treatment Becoming More Important?

Retinal vein occlusion (RVO) is a leading cause of vision impairment, often associated with underlying conditions such as hypertension, diabetes, and cardiovascular diseases. As RVO can lead to severe complications, including macular edema and neovascular glaucoma, the demand for effective treatment strategies has increased. Advances in pharmacotherapy, laser therapy, and surgical interventions have improved patient outcomes, helping to prevent further vision deterioration. The growing aging population, along with the increasing prevalence of metabolic disorders, has contributed to a rise in RVO cases worldwide. As a result, healthcare providers and researchers are focusing on developing more targeted and long-lasting treatment options.

How Are Technological Advancements Improving RVO Treatment Outcomes?

The development of anti-VEGF (vascular endothelial growth factor) therapy has transformed the treatment landscape for RVO-related macular edema, significantly reducing retinal swelling and improving visual acuity. Sustained-release corticosteroid implants have also been introduced, offering long-term benefits with fewer injections. Additionally, advancements in laser photocoagulation techniques, including micropulse laser therapy, have provided more precise treatment options with reduced side effects. AI-powered diagnostic tools and retinal imaging systems are enhancing early detection and personalized treatment planning, ensuring timely interventions for RVO patients. Moreover, emerging regenerative medicine approaches, including stem cell therapy, hold promise for restoring damaged retinal tissues and improving long-term prognosis.

What Market Trends Are Driving the Demand for RVO Treatments?

The increasing adoption of combination therapies, integrating anti-VEGF injections with laser treatments, has enhanced treatment efficacy while reducing the frequency of medical interventions. The expansion of teleophthalmology services has facilitated early diagnosis and remote monitoring, improving patient management. Additionally, the rise of home-based vision monitoring solutions, such as smartphone-based retinal imaging, is empowering patients to track their eye health and seek timely medical attention. Government-funded retinal disease screening programs and healthcare reimbursement policies are further driving market growth. As research continues to explore novel therapeutic approaches, including gene therapy and neuroprotection, the RVO treatment market is evolving rapidly.

What Are the Key Growth Drivers of the RVO Treatment Market?

The growth in the global retinal vein occlusion treatment market is driven by increasing incidences of diabetes and hypertension, advancements in pharmacological therapies, and improvements in retinal imaging technology. The widespread adoption of anti-VEGF therapy as a first-line treatment for RVO-related complications has significantly contributed to market expansion. Additionally, the growing availability of long-acting drug delivery systems is improving patient compliance and reducing treatment burden. The expansion of healthcare access in emerging markets, along with government-led initiatives for vision care, is further accelerating demand. As new therapeutic innovations continue to emerge, the RVO treatment market is expected to witness sustained growth, offering improved solutions for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Retinal Vein Occlusion Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion); Treatment (Anti-vascular Endothelial Factor, Corticosteroid Drugs, Others); End-Use (Hospital & Clinics, Retail Pharmacy, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Aerie Pharmaceuticals Inc.
  • Alimera Sciences Inc.
  • Annexin Pharmaceuticals AB
  • Bayer AG
  • Biocon Biologics Ltd
  • Bristol-Myers Squibb Company
  • Carl Zeiss Meditec AG
  • Chugai Pharmaceutical Co., Ltd
  • Ellex Medical Lasers Ltd
  • EyePoint Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lumenis Ltd.
  • Merck & Co., Inc.
  • NIDEK CO., LTD.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Retinal Vein Occlusion Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Hypertension and Cardiovascular Risk Factors Drives Incidence of Retinal Vein Occlusion
    • Rising Demand for Anti-VEGF and Corticosteroid Injections Throws the Spotlight on Pharmacologic Management
    • Expansion of Patient Access to Intravitreal Therapies Strengthens Business Case for RVO Treatment Portfolios
    • Development of Sustained-Release Implants Enhances Adherence and Reduces Treatment Burden
    • Clinical Research on Combination Therapies Propels Innovation in Managing Complex and Resistant RVO Cases
    • Integration of OCT Imaging and Angiography in Diagnostic Pathways Enhances Early Detection and Monitoring
    • Rising Emphasis on Personalized Therapy Selection Based on Occlusion Type Supports Precision Medicine Approaches
    • Increased Awareness Campaigns Around Ocular Stroke and Vascular Health Drives Early Intervention Rates
    • Regulatory Approvals for Long-Acting Formulations and New Drug Classes Expand Therapeutic Options
    • Expansion of Ophthalmology Clinics and Ambulatory Injection Facilities Accelerates Market Accessibility
    • Technological Advancements in Intraocular Injection Devices Improve Accuracy and Reduce Complications
    • Growing Pipeline of Novel Biologics and Biosimilars Enhances Competitive Landscape and Affordability
    • Inclusion of RVO Treatment in Public Health Eye Screening Programs Broadens Patient Outreach
    • Use of Adjunctive Laser Therapy in Ischemic RVO Supports Multimodal Treatment Strategies
    • Rising Research on Inflammation and Microvascular Involvement Spurs New Mechanism-Targeted Drugs
    • Shift Toward Evidence-Based Retreatment Protocols Improves Long-Term Visual Outcomes
    • Strategic Collaborations Between Pharma Companies and Retinal Specialists Drive Drug Adoption
    • Real-World Data and Clinical Registries Strengthen Post-Market Evidence for RVO Therapies
    • Reimbursement Expansion and Tiered Access Pricing Models Boost Treatment Uptake in Developing Regions
    • Global Burden of Vision Loss From RVO Accelerates Innovation in Both Diagnostic and Therapeutic Modalities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Retinal Vein Occlusion Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Central Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Central Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Branch Retinal Vein Occlusion by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Branch Retinal Vein Occlusion by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-vascular Endothelial Factor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-vascular Endothelial Factor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Retinal Vein Occlusion Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Retinal Vein Occlusion Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Retinal Vein Occlusion Treatment by Disease Type - Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Disease Type - Percentage Breakdown of Value Sales for Central Retinal Vein Occlusion and Branch Retinal Vein Occlusion for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Retinal Vein Occlusion Treatment by Treatment - Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by Treatment - Percentage Breakdown of Value Sales for Anti-vascular Endothelial Factor, Corticosteroid Drugs and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Retinal Vein Occlusion Treatment by End-Use - Hospital & Clinics, Retail Pharmacy and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Retinal Vein Occlusion Treatment by End-Use - Percentage Breakdown of Value Sales for Hospital & Clinics, Retail Pharmacy and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION